NZ604011A - Crystalline forms of thalidomide and processes for their preparation - Google Patents

Crystalline forms of thalidomide and processes for their preparation

Info

Publication number
NZ604011A
NZ604011A NZ604011A NZ60401111A NZ604011A NZ 604011 A NZ604011 A NZ 604011A NZ 604011 A NZ604011 A NZ 604011A NZ 60401111 A NZ60401111 A NZ 60401111A NZ 604011 A NZ604011 A NZ 604011A
Authority
NZ
New Zealand
Prior art keywords
thalidomide
anhydrous
alpha
crystalline
mixtures
Prior art date
Application number
NZ604011A
Other languages
English (en)
Inventor
Sandeep Mekde
Madhukar Patil
Vinayak Govind Gore
Vinay Kumar Shukla
Original Assignee
Generics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics Uk Ltd filed Critical Generics Uk Ltd
Publication of NZ604011A publication Critical patent/NZ604011A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ604011A 2010-06-09 2011-06-09 Crystalline forms of thalidomide and processes for their preparation NZ604011A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1758MU2010 2010-06-09
PCT/GB2011/051078 WO2011154739A1 (en) 2010-06-09 2011-06-09 Crystalline forms of thalidomide and processes for their preparation

Publications (1)

Publication Number Publication Date
NZ604011A true NZ604011A (en) 2015-04-24

Family

ID=44384914

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ604011A NZ604011A (en) 2010-06-09 2011-06-09 Crystalline forms of thalidomide and processes for their preparation

Country Status (8)

Country Link
US (2) US20130143923A1 (enExample)
EP (1) EP2580205A1 (enExample)
JP (1) JP2013528206A (enExample)
CN (1) CN103068812A (enExample)
AU (1) AU2011263493B2 (enExample)
CA (1) CA2801835A1 (enExample)
NZ (1) NZ604011A (enExample)
WO (1) WO2011154739A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102924432A (zh) * 2012-11-09 2013-02-13 常州制药厂有限公司 一种高纯度沙利度胺的制备方法
EP3010893B1 (de) * 2013-06-20 2019-10-02 Bayer CropScience Aktiengesellschaft Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
EP4649963A3 (en) * 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN104710411B (zh) * 2015-03-13 2017-04-26 安润医药科技（苏州）有限公司 阿伐那非的合成方法
CN110498788B (zh) * 2018-05-16 2021-09-17 欣凯医药化工中间体（上海）有限公司 一种高纯度沙利度胺α晶型的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB768821A (en) 1954-05-17 1957-02-20 Gruenenthal Chemie Novel products of the amino-piperidine-2, 6-dione series
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
CN1164586C (zh) 2002-10-28 2004-09-01 中国科学院长春应用化学研究所 沙利度胺及其衍生物的制备方法
US20050182097A1 (en) * 2003-12-30 2005-08-18 Zeldis Jerome B. Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
ITMI20041113A1 (it) * 2004-06-01 2004-09-01 Antibioticos Spa Processo per la sintesi della talidomide
WO2008035378A2 (en) * 2006-09-20 2008-03-27 Matrix Laboratories Ltd An improved process for the preparation of thalidomide
WO2009083724A1 (en) 2007-12-27 2009-07-09 Cipla Limited Processes for the preparation of thalidomide
CN102260241A (zh) * 2010-05-26 2011-11-30 重庆医药工业研究院有限责任公司 一种沙利度胺α晶型的工业化制备方法

Also Published As

Publication number Publication date
US20150218126A1 (en) 2015-08-06
EP2580205A1 (en) 2013-04-17
AU2011263493B2 (en) 2015-08-06
US20130143923A1 (en) 2013-06-06
AU2011263493A8 (en) 2013-02-21
AU2011263493A1 (en) 2013-01-10
WO2011154739A1 (en) 2011-12-15
CN103068812A (zh) 2013-04-24
CA2801835A1 (en) 2012-12-15
JP2013528206A (ja) 2013-07-08

Similar Documents

Publication Publication Date Title
DK3160962T3 (en) PROCEDURE FOR PREPARING A CONDENSED HETEROCYCLIC COMPOUND
NZ705827A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
NZ600119A (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
NZ599549A (en) Methods of synthesis and purification of heteroaryl compounds
UA101482C2 (ru) Способ получения 2'-дезокси-5-азацитидина (децитабина)
NZ586900A (en) Anhydrous polymorphic form b of bosentan and uses thereof
US10040793B2 (en) Key intermediates and impurities of the synthesis of Apixaban: Apixaban glycol esters
Jana et al. Copper-catalyzed addition of water affording highly substituted furan and unusual formation of naphthofuran ring from 3-(1-alkenyl)-2-alkene-1-al
WO2011114210A3 (en) Processes for the preparation of linezolid
Dennis et al. Procyanidin oligomers. A new method for 4→ 8 interflavan bond formation using C8-boronic acids and iterative oligomer synthesis through a boron-protection strategy
Zhang et al. An improved protocol for synthesis of N-arylamides and benzoxazoles by the copper-catalyzed reaction of aryl halides with nitriles
Wu et al. Tetrazole-1-acetic acid as a ligand for copper-catalyzed N-arylation of imidazoles with aryl iodides under mild conditions
ES2875126T3 (es) Proceso para la síntesis de pirfenidona
JP2015003875A (ja) リン系化合物及びその製造方法
IN2013MN02407A (enExample)
JPWO2015137216A1 (ja) ２−アシルイミノピリジン誘導体の製造法
Lakontseva et al. Diversity-oriented pyrazol-3-one synthesis based on hydrazinodipeptide-like units prepared via the Ugi reaction
KR20160027537A (ko) 실로도신의 제조방법
EP3242876A1 (en) An improved process for the preparation of lurasidone and its intermediate
HRP20200300T4 (hr) Novi polimorf ivabradin hidroklorida i metoda za njegovu pripremu
KR102436961B1 (ko) 할로-치환된 트리플루오로아세토페논의 제조 방법
CN109678757A (zh) 一种沙坦联苯及其衍生物的合成方法
WO2017081702A2 (en) A process for preparation of enzalutamide
KR20160074769A (ko) 실로도신의 결정형의 제조방법
CN106316999B (zh) 一种苯并呋喃-2,3-二酮肟衍生物的制备方法与应用

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: GENERICS (UK) LIMITED, GB

Effective date: 20140703

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 JUN 2018 BY COMPUTER PACKAGES INC

Effective date: 20150818

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUN 2019 BY RENEWALS TEAM

Effective date: 20180510

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUN 2020 BY RENEWALS TEAM

Effective date: 20190516

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUN 2021 BY ENVOY

Effective date: 20200609

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUN 2022 BY IPAN GMBH

Effective date: 20210526

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUN 2023 BY IPAN GMBH

Effective date: 20220526

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUN 2024 BY IPAN GMBH

Effective date: 20230526

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUN 2025 BY IPAN GMBH

Effective date: 20240527

LAPS Patent lapsed